Cartesian Stock Price, News & Analysis

Cartesian Therapeutics (NASDAQ: RNAC) announced promising 12-month data from its Phase 2b trial of Descartes-08, a CAR-T cell therapy for myasthenia gravis (MG). After a single six-week treatment course, patients showed sustained benefits with an average 4.8-point reduction in MG-ADL at Month 12.

Key highlights:

• Patients without prior biologic therapy exposure showed the strongest response, with a 7.1-point reduction in MG-ADL and 57% maintaining minimum symptom expression at Month 12
• 83% of evaluable participants maintained clinically meaningful response through Month 12
• Safety profile remained favorable with no cytokine release syndrome or neurotoxicity cases
• Treatment was administered in outpatient setting without chemotherapy

The company received FDA's RMAT and Orphan Drug Designations for Descartes-08, and plans to initiate the Phase 3 AURORA trial in Q2 2025.

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on autoimmune disease cell therapies, has granted inducement awards to four new employees. The awards consist of options to purchase a total of 31,000 shares of company common stock at an exercise price of $12.49 per share, matching the closing price on Nasdaq Global Market on April 1, 2025.

The options were issued under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and received board approval. The vesting schedule includes 25% vesting on April 1, 2026, followed by three equal annual installments, achieving full vesting by April 1, 2029. These ten-year term options were granted under Nasdaq Listing Rule 5635(c)(4) as employment inducements.

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's management will engage in a fireside chat scheduled for Tuesday, April 8, 2025, at 2:15 p.m. ET. Investors and interested parties can access the live webcast through the Events section of Cartesian's website at www.cartesiantherapeutics.com. An archived replay will be available for a time after the event.

Cartesian Therapeutics (NASDAQ: RNAC) has reported its full year 2024 financial results and provided key business updates. The company maintains a strong financial position with $214.3 million in cash and equivalents, expected to fund operations into mid-2027.

Key pipeline developments include:

• Phase 3 AURORA trial of Descartes-08 for myasthenia gravis set to begin in 1H25, supported by FDA Special Protocol Assessment agreement
• Positive Phase 2b trial results showing durable responses over 12 months in Descartes-08-treated participants
• Ongoing Phase 2 trial of Descartes-08 for systemic lupus erythematosus with data expected in 2H25
• Planned Phase 2 pediatric basket trial initiation in 2H25

Financial results show R&D expenses decreased to $45.1 million from $71.3 million in 2023, while G&A expenses reduced to $30.1 million from $40.5 million. Net loss for 2024 was $(77.4) million, or $(4.48) per share, compared to $(219.7) million in 2023.

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases, has granted an employment inducement award to a new employee. The award consists of an option to purchase 2,650 shares of company common stock at an exercise price of $17.50 per share, matching the closing price on Nasdaq Global Market on the grant date of March 3, 2025.

The option was issued under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and follows Nasdaq Listing Rule 5635(c)(4). The vesting schedule includes 25% vesting on March 3, 2026, followed by three equal annual installments, achieving full vesting by March 3, 2029. The option carries a ten-year term.

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases, has announced its participation in three upcoming investor conferences in February and March 2025:

• H.C. Wainright & Co. 3rd Annual Cell Therapy Virtual Conference - February 25, 2025, at 1:00 p.m. ET (fireside chat)
• TD Cowen 45th Annual Health Care Conference - March 3, 2025, at 1:50 p.m. ET in Boston, MA (presentation)
• Leerink Global Healthcare Conference - March 10, 2025, at 8:40 a.m. ET in Miami, FL (fireside chat)

Live webcasts of these events will be available in the Events section of Cartesian Therapeutics' website, with archived replays accessible for a time.

Cartesian Therapeutics (NASDAQ: RNAC) has granted inducement awards to five new employees on February 3, 2025. The awards consist of options to purchase a total of 168,360 shares of company common stock at an exercise price of $19.89 per share, matching the closing price on Nasdaq Global Market on the grant date.

The options were issued under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and received board approval. The vesting schedule includes 25% vesting on February 3, 2026, followed by three equal annual installments, achieving full vesting by February 3, 2029. The options have a ten-year term and were granted under Nasdaq Listing Rule 5635(c)(4).

Cartesian Therapeutics (NASDAQ: RNAC) has secured FDA Special Protocol Assessment (SPA) agreement for its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG). The trial is scheduled to begin in first half of 2025. The SPA agreement confirms that the trial design could support a future Biologics License Application.

The Phase 3 AURORA trial will be randomized, double-blind, and placebo-controlled, involving approximately 100 participants with AChR Ab+ MG. The study will evaluate Descartes-08 versus placebo with six weekly infusions without preconditioning chemotherapy. The primary endpoint will measure improvement in MG-ADL score.

Recent Phase 2b trial results showed promising outcomes, with treated participants (n=12) achieving an average MG-ADL reduction of 5.5 at Month 4. The therapy demonstrated good tolerability, supporting outpatient administration without requiring lymphodepleting chemotherapy.

Cartesian Therapeutics (NASDAQ: RNAC) has outlined its 2025 strategic priorities for its mRNA cell therapy pipeline. The company's lead candidate, Descartes-08, showed promising Phase 2b results in myasthenia gravis (MG), with participants experiencing an average MG-ADL reduction of 5.5 at Month 4. The Phase 3 AURORA trial for MG is set to begin in 1H25.

The company is also advancing Descartes-08 in other indications, with an ongoing Phase 2 trial in systemic lupus erythematosus (SLE) expected to report data in 2H25, and plans to start a Phase 2 basket trial in pediatric autoimmune diseases in 2025. Additionally, dosing is underway in a Phase 1 trial of Descartes-15, their next-generation anti-BCMA mRNA CAR-T cell therapy.

Cartesian's cash resources are expected to support planned operations, including the Phase 3 trial completion, into mid-2027.